Marty Makary wasn’t the only official on the outs at FDA last week in another tumultuous turn of events for the regulatory agency. On the latest BioCentury This Week podcast, BioCentury Washington Editor Steve Usdin discusses who’s in, who’s out and what’s next at FDA — and why the changes may mean more conservative decision-making at the agency in the near term.
BioCentury’s analysts also discuss the new obesity targets that came to light at last week’s annual meeting of the European Congress on Obesity, the market for biotech IPOs, and the emergence of degrader-antibody conjugates. DACs pair the tissue-targeting logic of antibody-drug conjugates (ADCs) with the catalytic activity of protein degraders. 3C Therapeutics is the latest entrant to the field, pitching its TriCore platform as a modular backbone for DAC generation. This episode of the BioCentury podcast is brought to you by Jeito Capital.

View full story: https://www.biocentury.com/article/659510

#FDA #ObesityDrugDevelopment #BiotechIPO #DACs #Biopharma

00:01 - Sponsor Message: Jeito Capital
02:53 - FDA Leadership Shakeup
10:35 - Obesity Target Hunt
16:07 - Biotech IPOs
20:02 - Degrader-antibody Conjugates
28:42 - Serif: Non-viral DNA

To submit a question to BioCentury’s editors, email the BioCentury This Week team at podcasts@biocentury.com.

Reach us by sending a text

Ep. 367 - FDA, obesity targets and the rise of DACs

BioCentury This Week

Ep. 367 - FDA, obesity targets and the rise of DACs